Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy
Background and purpose: Programmed death-1 (PD-1) monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma (HNSCC). However, low response rate and lack of predictive biomarkers are still the challenging problems. This study aimed to c...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-06-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1690339627273-1495212812.pdf |
| _version_ | 1797768980484587520 |
|---|---|
| author | HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou |
| author_facet | HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou |
| author_sort | HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou |
| collection | DOAJ |
| description | Background and purpose: Programmed death-1 (PD-1) monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma (HNSCC). However, low response rate and lack of predictive biomarkers are still the challenging problems. This study aimed to confirm that programmed death ligand-2 (PD-L2) is a predictive biomarker for the outcome of HNSCC anti-PD-1 immunotherapy. Methods: The samples and clinical data of 50 HNSCC patients undergoing PD-1 monoclonal antibody immunotherapy were collected. Immunohistochemical staining was used to analyze the level of programmed death ligand-1 (PD-L1) and PD-L2. Kaplan-Meier overall survivals were analyzed using SPSS 26.0 software, grouped by the basic clinical characteristics and the PD-L1 and PD-L2 levels. Survival curves were plotted using GraphPad Prism. Results: HNSCC had a relatively high expression rate of PD-L2 with more than 80% of cases detected as PD-L2 positive. The expression of PD-L2 significantly correlated with the clinical outcome of immunotherapy, with a mean survival of 18.8 (16.0-21.7) months for patients with high PD-L2 expression and 11.0 (9.1-12.8) months for patients with low PD-L2 expression, this difference being statistically significant. Conclusion: PD-L2 has the potential to be used as a predictive biomarker for HNSCC anti-PD-1 immunotherapy. |
| first_indexed | 2024-03-12T21:02:12Z |
| format | Article |
| id | doaj.art-9ddba1fbb92f4f35af26fbe053edd378 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-03-12T21:02:12Z |
| publishDate | 2023-06-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-9ddba1fbb92f4f35af26fbe053edd3782023-07-31T05:44:07ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392023-06-0133661361810.19401/j.cnki.1007-3639.2023.06.009Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapyHUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou0Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology, Shanghai 200011, ChinaBackground and purpose: Programmed death-1 (PD-1) monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma (HNSCC). However, low response rate and lack of predictive biomarkers are still the challenging problems. This study aimed to confirm that programmed death ligand-2 (PD-L2) is a predictive biomarker for the outcome of HNSCC anti-PD-1 immunotherapy. Methods: The samples and clinical data of 50 HNSCC patients undergoing PD-1 monoclonal antibody immunotherapy were collected. Immunohistochemical staining was used to analyze the level of programmed death ligand-1 (PD-L1) and PD-L2. Kaplan-Meier overall survivals were analyzed using SPSS 26.0 software, grouped by the basic clinical characteristics and the PD-L1 and PD-L2 levels. Survival curves were plotted using GraphPad Prism. Results: HNSCC had a relatively high expression rate of PD-L2 with more than 80% of cases detected as PD-L2 positive. The expression of PD-L2 significantly correlated with the clinical outcome of immunotherapy, with a mean survival of 18.8 (16.0-21.7) months for patients with high PD-L2 expression and 11.0 (9.1-12.8) months for patients with low PD-L2 expression, this difference being statistically significant. Conclusion: PD-L2 has the potential to be used as a predictive biomarker for HNSCC anti-PD-1 immunotherapy.http://www.china-oncology.com/fileup/1007-3639/PDF/1690339627273-1495212812.pdf|head and neck squamous cell carcinoma|immunotherapy|programmed death ligand-2 |
| spellingShingle | HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy Zhongguo aizheng zazhi |head and neck squamous cell carcinoma|immunotherapy|programmed death ligand-2 |
| title | Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy |
| title_full | Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy |
| title_fullStr | Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy |
| title_full_unstemmed | Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy |
| title_short | Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy |
| title_sort | clinical implication of pd l2 in the prognosis assessment of hnscc immunotherapy |
| topic | |head and neck squamous cell carcinoma|immunotherapy|programmed death ligand-2 |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1690339627273-1495212812.pdf |
| work_keys_str_mv | AT huanghejuhouyuyangwenyiyanmingrenguoxinhujingzhou clinicalimplicationofpdl2intheprognosisassessmentofhnsccimmunotherapy |